PYC Therapeutics Completes VP-001 toxicology studies, eyes human trials
- PYC Therapeutics (PYC) completes single-dose toxicology of its investigational Retinitis Pigmentosa type 11 (RP11) treatment drug candidate
- According to PYC, the studies proved the drug was safe and well-tolerated at all dose levels assessed, paving the way for first in-human studies of the treatment
- The company anticipates filing an investigational new drug application in support of VP-001 before the end of this year
- If successful, PYC then plans to progress to human clinical trials in the first quarter of 2023
- Shares in PYC are up 2.86 per cent to 7.2 cents at 3:45 pm AEDT
